PerkinElmer Life Sciences Announces a Fully Automated Workstation for Nucleic Acid Normalization

07-Aug-2002

BOSTON Aug. 5, 2002 - PerkinElmer Life Sciences, today announced availability of a new integrated workstation for automated, high-throughput normalization of nucleic acid samples. Normalization is a technique that standardizes sample concentration to improve the quality of downstream applications, such as sequencing reactions, microarray construction, multiplexing PCR, gene expression and protein binding assays.

PerkinElmer has partnered with Molecular Devices Corporation to co-market the new MultiPROBE(R) II Nucleic Acid Normalization Workstation. The workstation provides full walk-away automation for nucleic acid quantification and normalization through the use of PerkinElmer's MultiPROBE II Robotic Liquid Handling System with Gripper(TM) Integration Platform, new nucleic acid normalization software and an integrated SpectraMax(R) plate reader from Molecular Devices.

Incorporation of the Molecular Devices' SpectraMax plate reader enables PerkinElmer to offer a workstation that supports quantification via UV absorbance or fluorescence detection. The Nucleic Acid Normalization Workstation can setup a 96 well plate for quantification in as little as 7 minutes. Normalization can be achieved in as little as 8 minutes for a 96 well.

Other news from the department research and development

Most read news

More news from our other portals

So close that even
molecules turn red...

Last viewed contents

Cerenis Therapeutics raises additional €10 million to close €50 million Series C financing

Genetic mutations that lead to macular degeneration blindness mapped by new research

Genetic mutations that lead to macular degeneration blindness mapped by new research

Barroso Commission recognises contribution of biotech crops to European competitiveness

BioVaria Start-up Awards go to ISD Immunotech and Mindpax.me

Alnylam Announces Manufacturing Agreement with Dowpharma(TM) for RNAi Therapeutics

Atugen AG raises EUR 5 million venture funding for siRNA therapeutics program - siRNA therapeutics patent application published

Vantia Therapeutics’ lead candidate VA106483 enters Phase IIb trial for nocturia

Organon and Schering to continue research in male fertility control separately

A human enzyme (CD 39) targets the Achilles heel of sepsis - New research suggests that CD39 significantly improves survival of mice in severe sepsis

Borean Pharma Acquires Proteopharma and Promising Arterial Drug

Vernalis extends cancer research collaboration with Novartis Institutes for BioMedical Research - Joint research and development programme on Hsp90, a target implicated in a number of different cancers - Vernalis to receive a $1.5 million signature fee - Novartis to make an investment in new Vernalis shares of approximately ?5 million

Horizon Discovery Group plc, Centre for Process Innovation and University of Manchester Awarded £1.67M - Consortium to receive funding to develop enhanced biomanufacturing platforms based on the Company’s CHO cell line and gene editing platform